Daniel Bonner, Ph.D., Co-founder and Senior Vice President at Seaport Therapeutics, highlighted the clinical validation of the Glyph platform and its application across Seaport's pipeline ...

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... Seaport said the money would support a pipeline of improved neuropsychiatric drug ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel ...

About Seaport Therapeutics Seaport Therapeutics is a ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely ...

Hombach’s appointment comes at a pivotal time for Seaport, which is focused on advancing its pipeline of neuropsychiatric therapeutics. The company’s proprietary Glyph technology platform ...

BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical ... his expertise would be invaluable as Seaport advances its pipeline of potential neuropsychiatric medicines.

including without limitation those related to Seaport’s development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph Platform, the applicability of the platform beyond ...

Seaport Therapeutics is a clinical-stage biopharmaceutical ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is ...

BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company ... She highlighted that his expertise would be invaluable as Seaport advances its pipeline of potential neuropsychiatric ...

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that ...